by Truveta Research | Jun 26, 2025 | Research, Research Insights
Thimerosal is a preservative contained in some vaccines, which has been used and considered safe for decades. During the June 2025 ACIP meeting, a presentation and vote on the use of thimerosal is scheduled to take place. During the 2024-2025 respiratory virus season,...
by Truveta Research | May 16, 2025 | Research, Research Insights
Among children in Texas receiving a first measles vaccine prior to two years of life: In March and April 2025, 20.1% of all first measles vaccines were administered to children early (6-11 months). This is 11.5-fold higher than in 2019, when there were international...
by Truveta Research | Apr 3, 2025 | Research, Research Insights
The vaccination rate by age six fluctuated between 2018 and 2021; however, rates have decreased since 2021. The rate in 2021 was 81.9% compared to 80.4% in 2024. This means for every 70 children, roughly one more child received two measles vaccines in 2021 compared to...
by Truveta Research | Apr 3, 2025 | Research, Research Insights
Measles vaccination rates for children under 24 months in 2024 remain lower than in 2020. In 2024, the average yearly measles vaccination rate for children by 13 months was 58.9% and 68.5% for children by 15 months. Vaccination patterns for children living in both...
by Terry Myerson, CEO | Mar 27, 2025 | News
At Truveta, our mission is Saving Lives with Data, and we are thinking about the HHS leadership mission of making American’s healthier, and how to help the talented scientists of HHS do more with less. We’d like to contribute to this important mission – starting...
